Login to Your Account



BioMarin Launches Phase III Program for Phenylketonuria

By Catherine Shaffer
Staff Writer

Wednesday, June 5, 2013

Execs at BioMarin Pharmaceutical Inc. hope to repeat their Phase II success with PEG-PAL (PEGylated recombinant phenylalanine ammonia lysate) for phenylketonuria in a new Phase III program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription